<DOC>
	<DOCNO>NCT01542060</DOCNO>
	<brief_summary>This study conduct Asia . The aim observational study collect efficacy safety data biphasic insulin aspart ( NovoMixÂ® 30 ) type 2 diabetes normal clinical practice condition .</brief_summary>
	<brief_title>Efficacy Safety Biphasic Insulin Aspart 30 Treatment Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Subjects hospital clinic , diagnose type 2 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>